UNSPSC 51294418: Befuraline hydrochloride

This classification denotes a phosphodiesterase inhibitor and antidepressant agent with the molecular formula C20H20N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4AF205SN5K, chemically known as piperazine, 1-(2-benzofuranylcarbonyl)-4-(phenylmethyl)-, monohydrochloride but more generally known as befuraline hydrochloride, which bears US NIH Compound Identifier 73346. The base compound, Befuraline, most often comes in base and hydrochloride forms.

Most nations, for tariff and trade purposes, schedule befuraline hydrochloride under HS 29349990. As of Q4 2014, BEFURALINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)CN2CCN(CC2)C(=O)C3CC4CCCCC4O3.CL.

UNSPSC 51294418 Befuraline hydrochloride is a Commodity code that does not align with the recent state and local opportunities posted under this classification. The three most recent solicitations tracked against this code involve naloxone procurement, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceuticals and OTC products — none of which concern befuraline hydrochloride specifically. The mismatch suggests either miscoding in the source records or that befuraline hydrochloride is not presently a focus of state and local procurement activity. The code shows no relevant recent opportunities.

Buyers using this code span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Seminole County, Florida procured naloxone and drug deactivation systems through an IFB posted June 30, 2026, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued an RFI in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP on January 20, 2026, with a response deadline of March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon. The code does not presently surface opportunities for befuraline hydrochloride procurement at state or local level.